Relapsed/refractory multiple myeloma-transformed plasma-cell leukemia successfully treated with daratumumab followed by autologous stem cell transplantation
Relapsed/refractory multiple myeloma-transformed plasma-cell leukemia successfully treated with daratumumab followed by autologous stem cell transplantation
Blog Article
Daratumumab is a humanized anti-CD38 IgG1 monoclonal antibody which could be used for multiple myeloma (MM).MM with plasma-cell leukemia (PCL) transformation is highly aggressive and is resistant to conventional therapy.Novel therapeutics are needed for PCL, and daratumumab may play role.We report a case of relapsed/refractory multiple myeloma (RRMM)-transformed PCL successfully treated with daratumumab.
The case was a 42-year-old man who was diagnosed with MM 2 years ago and relapsed after six cycles of bortezomib-based chemotherapy.The patient rapidly developed hyperleukocytosis and disseminated intravascular coagulation, and was diagnosed with PCL.Daratumumab-based therapy was Neuw Rebel Skinny Eternal Black Jeans tried and the case miraculously obtained complete remission (CR) after four doses of a weekly infusion of daratumumab.Finally the patient received autologous hematopoietic stem-cell transplantation (auto-HSCT) and maintained CR.
Moreover, we monitored the immune cell dynamics by flow cytometry (FCM) during daratumumab-based treatment.The immune cell subset analysis revealed significant down-regulation of CD38+ natural killer (NK) cells, regulatory T cells (Tregs) and regulatory B cells (Bregs).Meanwhile cytotoxic T-lymphocyte expansion was observed.In conclusion, daratumumab could rapidly decrease tumor burden, improve the condition of the PCL patient, and serve as a bridging salvage chemotherapy for further chimeric antigen recptor T cell therapy (Car-T) or HSCT, which could potentially improve patient survival.
The immune cell dynamic findings in this case suggest that the immunomodulatory mechanism may contribute to the replica beach walk candle antimyeloma effect of daratumumab.